Search Result

Results for "

Tumor targeting peptide

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Peptide-Drug Conjugates (PDCs) (4) TNF Receptor (3) ADC Linker (2) Akt (1) Amino Acid Derivatives (2) Antibody-Drug Conjugates (ADCs) (1) Antifolate (2) Apoptosis (6) Autophagy (1) Bcl-2 Family (1) Biochemical Assay Reagents (45) Bombesin Receptor (1) Cadherin (1) Carbonic Anhydrase (1) Caspase (4) CD3 (1) Collagen (1) Complement System (6) CXCR (4) DNA/RNA Synthesis (1) Drug Derivative (3) Drug Intermediate (2) EBV (2) EGFR (5) Epigenetic Reader Domain (3) ERK (1) FAP (3) Fluorescent Dye (1) Folate Receptor (FR) (2) G-quadruplex (1) GSK-3 (1) Histone Demethylase (1) Histone Methyltransferase (1) HSP (1) IFNAR (2) Integrin (10) Interleukin Related (1) Liposome (25) Melanocortin Receptor (1) MHC (4) Mitochondrial Metabolism (1) MMP (2) MOFs (1) Nectin-4 (1) NF-κB (2) P-selectin (1) PD-1/PD-L1 (3) PI3K (1) Protein Arginine Deiminase (1) PSMA (1) Radionuclide-Drug Conjugates (RDCs) (23) Ras (1) Reference Standards (2) Ser/Thr Kinase (1) STAT (1) Topoisomerase (1) Transferrin Receptor (1) Transmembrane Glycoprotein (1) TRP Channel (1) ULK (1) VEGFR (6) YAP (1)
By Research Areas:	Cancer (113) Cardiovascular Disease (3) Inflammation/Immunology (8) Metabolic Disease (2) Neurological Disease (1)
Click Chemistry:	Azide (2) Alkynes (4)
Oligonucleotides:	Pegylated Lipids (22)

141

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Click Chemistry

Oligonucleotides

Targets Recommended: Large Tumor Suppressor (LATS) TNF Receptor RXFP Receptor Formyl Peptide Receptor (FPR) Peptide-Drug Conjugates (PDCs) BRK Natriuretic Peptide Receptor (NPR) Connective Peptide CGRP Receptor Amyloid-β

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0122

iRGD peptide 5+ Cited Publications c(CRGDKGPDC)	Integrin	Cancer
iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.

HY-W053583

Tetraxetan 1 Publications Verification DOTA	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Cancer
Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

HY-P10761

DPI-4452	Radionuclide-Drug Conjugates (RDCs) Carbonic Anhydrase	Cancer
DPI-4452 is a *CAIX*-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC₅₀ for recombinant hCAIX: 130 nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models . DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-172494

DSPE-PEG2000-iRGD	Liposome Integrin Drug Intermediate Complement System	Cancer
DSPE-PEG2000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG2000-iRGD can be used for agent delivery .

HY-P10709

CREKA peptide	Collagen	Cardiovascular Disease Cancer
CREKA peptide is a selective non-covalent binding agent targeting fibrin, type IV collagen, and fibronectin, often used as a targeting ligand to modify delivery carriers. CREKA peptide specifically recognizes fibrin, fibronectin, and type IV collagen that are excessively deposited in the tumor microenvironment or fibrotic tissue, mediating the targeted accumulation of the carrier at the lesion site and promoting drug internalization into target cells (such as cancer cells and activated hepatic stellate cells). CREKA peptide can enhance targeted delivery efficiency, increase drug concentration at the lesion site, and reduce systemic side effects .

HY-W539916

Azido-mono-amide-DOTA	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
Azido-mono-amide-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Azido-mono-amide-DOTA can be used for conjugation of peptides and radionuclides.

HY-P10787

tLyP-1 peptide	Complement System	Cancer
tLyP-1 peptide is an NRP-1 targeting peptide with an IC₅₀ of 4 μM, and its amino acid sequence is CGNKRTR. tLyP-1 peptide specifically binds to NRP-1 to target tumor cells .

HY-P10131

3BP-3940	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases .

HY-P3440

WL12	Radionuclide-Drug Conjugates (RDCs) PD-1/PD-L1	Cancer
WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression .

HY-W749603

Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester)	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Cancer
Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester) is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester) can be used for conjugation of peptides and radionuclides.

HY-P3441A

3BP-4089 TFA	FAP	Cancer
3BP-4089 TFA is a highly efficient fibroblast activation protein (FAP) targeting peptide. 3BP-4089 TFA is often conjugated with radionuclides for tumor diagnosis and research .

HY-P11294

KLVVVGADGVGKSALTI	Ras	Cancer
KLVVVGADGVGKSALTI is a KRAS G12D targeting peptide that can be used in tumor research .

HY-P10493

NY-ESO-1 (157-165) peptide	Amino Acid Derivatives	Cancer
NY-ESO-1 (157-165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .

HY-W678394

DOTA-Thiol	Biochemical Assay Reagents	Others
DOTA-Thiolis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-Thiol can be used for conjugation of peptides and radionuclides.

HY-48876

p-NH2-Bn-DOTA	Biochemical Assay Reagents	Others
p-NH2-Bn-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-DOTA can be used for conjugation of peptides and radionuclides.

HY-P10501A

FRα-targeting peptide C7 TFA	Antifolate	Cancer
FRα-targeting peptide C7 TFA is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 TFA can be used in the research of tumor diagnosis and treatment .

HY-P10709A

CREKA peptide acetate	Biochemical Assay Reagents	Cardiovascular Disease Cancer
CREKA peptide acetate is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. CREKA peptide acetate can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .

HY-P10792

HER2-targeted peptide H6F	EGFR	Cancer
HER2-targeted peptide H6F is a HER2 targeting peptide that binds to HER2 to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .

HY-P4091

LSD	Biochemical Assay Reagents	Cancer
LSD is a peptide. LSD can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD can reduce the number of tumor lymphatics. LSD can be used in the research of targeted therapy and diagnosis of tumor lymphatics .

HY-W782078

Butyne-DOTA	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
Butyne-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA can be used for conjugation of peptides and radionuclides.

HY-W717779

4-Aminobutyl-DOTA	Biochemical Assay Reagents	Others
4-Aminobutyl-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. 4-Aminobutyl-DOTA can be used for conjugation of peptides and radionuclides.

HY-A0074

DTPA-tetra (t-Bu ester) tetra-tBu-DTPA	Biochemical Assay Reagents	Others
DTPA-tetra (t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. DTPA-tetra (t-Bu ester) can be used for conjugation of peptides and radionuclides.

HY-W717800A

NO2A-Azide trihydrochloride	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
NO2A-Azide (trihydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Azide (trihydrochloride) can be used for conjugation of peptides and radionuclides.

HY-P3441

3BP-4089	FAP	Cancer
3BP-4089 is a highly efficient fibroblast activation protein (FAP) targeting peptide. 3BP-4089 is often conjugated with radionuclides for tumor diagnosis and research .

HY-P10679

GPLGLAGGWGERDGS	MMP	Cancer
GPLGLAGGWGERDGS is a peptide with MMP enzyme responsiveness and tumor targeting function, which can be used to monitor enzyme-guided nanoparticle assembly in tumors .

HY-P1828A

EGFRvIII peptide (PEPvIII) TFA	EGFR	Cancer
EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide TFA represents a truly tumor-specific target for antitumor immunotherapy .

HY-P10894

mUNO	Epigenetic Reader Domain	Cancer
mUNO is a tumor-homing peptide (mUNO, sequence: "CSPGAK") that specifically binds to mouse CD206, targeting tumor-associated macrophages that express CD206/MRC1. mUNO can interact with human recombinant CD206 .

HY-W451440

Butyne-DOTA-tris(t-butyl ester)	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
Butyne-DOTA-tris(t-butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA-tris(t-butyl ester) can be used for conjugation of peptides and radionuclides.

HY-P11084

WT1 126-134 peptide	MHC	Inflammation/Immunology Cancer
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (K_d = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies .

HY-D2439

RGD-PEG-Cy3	Fluorescent Dye	Cancer
RGD-PEG-Cy3 is a fluorescent labeling reagent that combines Cy3 fluorescent dye, peptide (RGD) and polyethylene glycol (PEG). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. RGD is a peptide sequence (CRGDKGPDCiRGD) that binds to αvβ3 and αvβ5 integrin receptors on tumor neovasculogenesis to achieve specific tumor tissue targeting .

HY-158066

p-NH2-Bn-NOTA hydrochloride hydrate	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
p-NH2-Bn-NOTA (hydrochloride hydrate)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. p-NH2-Bn-NOTA (hydrochloride hydrate) can be used for conjugation of peptides and radionuclides.

HY-P11026

DOTA-TMVP1446 DOTA-PEG4-TMVP1446	VEGFR	Cancer
DOTA-TMVP1446 is a VEGFR-3 targeting peptide. DOTA-TMVP1446 labeled with ⁶⁸Ga accurately detectes the status of lymph node metastasis, even in micrometastatic tumors, in the B16-F10 tumor mice model. DOTA-TMVP1446 can be used as a radiotracer for cancer-metastatic sentinel lymph nodes (m-SLN) imaging .

HY-P1828

EGFRvIII peptide (PEPvIII)	EGFR	Cancer
EGFRvIII peptide (PEPvIII) is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide represents a truly tumor-specific target for antitumor immunotherapy .

HY-P11286

A7RC	Complement System	Cancer
A7RC is a multifunctional peptide used in tumor-targeted therapy, with Cysteine added to the C-terminal of the A7R peptide (sequence: ATWLPPR). A7R (HY-P1663) is a ligand of the NRP-1 receptor, regulating intracellular signal transduction related to tumor vascularization and tumor growth .

HY-P10493A

NY-ESO-1 (157-165) peptide TFA	Amino Acid Derivatives	Cancer
NY-ESO-1 (157-165) peptide (TFA) is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide (TFA) can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide (TFA) is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .

HY-172473

DSPE-PEG2000-NGR	Liposome	Cancer
DSPE-PEG2000-NGR is a PEG compound which composed of DSPE and an Asn-Gly-Arg (NGR) peptide. NGR peptide can target tumor vascular antigen CD13. DSPE-PEG2000-NGR can be used for drug delivery .

HY-131673A

(S)-p-SCN-Bn-TCMC hydrochloride	Biochemical Assay Reagents	Others
(S)-p-SCN-Bn-TCMC (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (S)-p-SCN-Bn-TCMC (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-178489

BGC1614	Nectin-4	Cancer
BGC1614 is a *Nectin-4*-targeting bicyclic toxin conjugate (BTC) belonging to the category of peptide-drug conjugates (PDCs). BGC1614 exhibits strong targeted binding ability to Nectin-4, with an K_D of 3.859 × 10 ^-7 M. BGC1614 exhibits superior antitumor efficacy in nude mice bearing PC-3 and N87 tumor xenografts. BGC1614 can be used for research related to Nectin-4-overexpressing tumors (such as prostate cancer, gastric cancer) .

HY-148646A

p-NH2-CHX-A"-DTPA hydrochloride hydrate	Biochemical Assay Reagents	Others
p-NH2-CHX-A"-DTPA (hydrochloride hydrate)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-NH2-CHX-A"-DTPA (hydrochloride hydrate) can be used for conjugation of peptides and radionuclides.

HY-P10501

FRα-targeting peptide C7	Antifolate	Cancer
FRα-targeting peptide C7 is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 can be used in the research of tumor diagnosis and treatment .

HY-172497

DSPE-PEG2000-Mal-Cys-REKA	Liposome	Cancer
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .

HY-P10786

LinTT1 peptide	Transmembrane Glycoprotein	Cancer
LinTT1 peptide is a tumor-penetrating peptide with the amino acid sequence AKRGARST. LinTT1 peptide targets peritoneal carcinoma (PC) by binding to the p32 (gC1qR) receptor. It can conjugate with iron oxide nanoworms (NWs) to form a nanocarrier. This nanocarrier is taken up by peritoneal carcinoma cells in vitro and enters the mitochondria; it also exhibits significant tumor targeting and penetration effects in mice. Moreover, LinTT1-functionalized nanocarriers, combined with the pro-apoptotic peptide [D(KLAKLAK)2], show significant tumor suppression in a mouse peritoneal tumor model. LinTT1 peptide holds promise as a delivery carrier for peritoneal cancer research .

HY-172494A

DSPE-PEG3400-iRGD	Liposome Integrin	Cancer
DSPE-PEG3400-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3400-iRGD can be used for drug delivery .

HY-138134

NOTP	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) MOFs	Others
NOTPis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NOTP can be used for conjugation of peptides and radionuclides.

HY-W088413

DOTA-amide	Biochemical Assay Reagents	Others
DOTA-amideis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-amide can be used for conjugation of peptides and radionuclides.

HY-P5520

GB-6	Bombesin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
GB-6 is a short linear peptide that targets the gastrin releasing peptide receptor (GRPR). GRPR is overexpressed in pancreatic cancer. Based on the tumor selectivity and tumor-specific accumulation properties of GB-6, GB-6 labeled with near infrared (NIR) fluorescent dyes or radionuclide netium-99m (99mTc) can be used as a high-contrast imaging probe. GB-6 has excellent in vivo stability, with tumor to pancreatic and intestinal fluorescence signal ratios of 5.2 and 6.3, respectively, in SW199 0 subcutaneous xenograft models. GB-6 can rapidly target tumors and accurately delineate tumor boundaries, which has broad application prospects .

HY-W250844A

DO3A trisodium	Biochemical Assay Reagents	Others
DO3A (trisodium)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DO3A (trisodium) can be used for conjugation of peptides and radionuclides.

HY-128890A

DOTA-NHS-ester hexafluorophosphate TFA	Biochemical Assay Reagents	Others
DOTA-NHS-ester (hexafluorophosphate TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-NHS-ester (hexafluorophosphate TFA) can be used for conjugation of peptides and radionuclides.

HY-W782087A

p-SCN-Bn-PCTA hydrochloride	Biochemical Assay Reagents	Others
p-SCN-Bn-PCTA (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-SCN-Bn-PCTA (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-P3707

Tumor targeted pro-apoptotic peptide	Apoptosis	Cancer
Tumor targeted pro-apoptotic peptide (CNGRC-GG-D(KLAKLAK)2) is an anti-tumor peptide. Tumor targeted pro-apoptotic peptide disrupts mitochondrial membranes and promotes apoptosis, showing anticancer activity in mice .

Cat. No.	Product Name

HY-L110

Cyclic Peptide Library

97 compounds

Cyclic peptides are polypeptide chains taking cyclic ring structure, which exhibit diverse biological activities, such as antibacterial activity, immunosuppressive activity and anti-tumor activity. Cyclic peptides, with the features of good binding affinity, target selectivity and low toxicity, show great success as therapeutics. Multiple cyclic peptides are currently in clinical use, for examples, gramicidin and tyrocidine with bactericidal activity, cyclosporin A with immunosuppressive activity, and vancomycin with antibacterial activity. Furthermore, cyclic peptides usually have the sufficient size and a balanced conformational flexibility/rigidity for binding to flat protein-protein interaction (PPI) interfaces, which have potential to develop PPI drugs.

MCE offers a unique collection of 97 cyclic peptides, all of which have good bioactivities. MCE Cyclic Peptide Library is a powerful tool for drug discovery and PPI inhibitor screening.

HY-L932V0

Kinase Macrocyclic Compound Virtual Library

2,000,000 compounds

Macrocyclic compounds (≥12-atom cyclic small molecules/peptides) have unique physicochemical properties. They form preorganized conformations with high binding affinity/selectivity, target traditional small-molecule-inaccessible proteins, and bridge small-molecule drugs and biological agents. As key protein phosphorylation enzymes, kinases are linked to tumors, COPD, etc., and are critical therapeutic targets. Traditional small-molecule kinase inhibitors lack selectivity, causing off-target toxicity, low bioavailability, and acquired resistance. Macrocycles’ semi-rigid structure restricts conformations, boosts binding selectivity, optimizes pharmacokinetics, and makes macrocyclization a core kinase inhibitor optimization strategy.

Thousands of bioactive macrocycles were curated from ChEMBL. Via Transformer, macrocyclization was converted into a chemical language translation task, enabling end-to-end macrocycle generation from linear precursors with simplified inputs. Macformer achieves efficient, automated linear molecule macrocyclization via deep learning; generated macrocycles have diversity, novelty, biocompatibility, and cover broader chemical space.

MCE collected thousands of marketed/clinical kinase inhibitors, using their fragments for macrocyclization to generate derivatives. After evaluating synthetic accessibility and physicochemical properties, a million-scale virtual macrocyclic library was built for kinase-related virtual and AI-driven screening.

HY-L932V

Kinase Macrocyclic Compound Virtual Library

2,000,000 compounds

Cat. No.	Product Name	Type

HY-P3371

Ifinatamab deruxtecan

DS-7300a; MABX-9001a; I-DXd

Fluorescent Dyes

Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects

HY-D2439

RGD-PEG-Cy3

Fluorescent Dyes

RGD-PEG-Cy3 is a fluorescent labeling reagent that combines Cy3 fluorescent dye, peptide (RGD) and polyethylene glycol (PEG). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. RGD is a peptide sequence (CRGDKGPDCiRGD) that binds to αvβ3 and αvβ5 integrin receptors on tumor neovasculogenesis to achieve specific tumor tissue targeting .

HY-D2334

AlF-NOTA-c-d-VAP	Fluorescent Dyes
AlF-NOTA-c-d-VAP is a peptide positron emission tomography (PET) probe that used for targeted tumor imaging of GRP78. AlF-NOTA-c-d-VAP demonstrates high stability in vitro and in vivo .

Cat. No.	Product Name	Type

HY-W053583

Tetraxetan

1 Publications Verification

DOTA

Biochemical Assay Reagents

Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

HY-172494

DSPE-PEG2000-iRGD	Biochemical Assay Reagents
DSPE-PEG2000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG2000-iRGD can be used for agent delivery .

HY-W539916

Azido-mono-amide-DOTA	Biochemical Assay Reagents
Azido-mono-amide-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Azido-mono-amide-DOTA can be used for conjugation of peptides and radionuclides.

HY-W749603

Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester)	Biochemical Assay Reagents
Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester) is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester) can be used for conjugation of peptides and radionuclides.

HY-W678394

DOTA-Thiol	Biochemical Assay Reagents
DOTA-Thiolis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-Thiol can be used for conjugation of peptides and radionuclides.

HY-48876

p-NH2-Bn-DOTA	Biochemical Assay Reagents
p-NH2-Bn-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-DOTA can be used for conjugation of peptides and radionuclides.

HY-W782078

Butyne-DOTA	Biochemical Assay Reagents
Butyne-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA can be used for conjugation of peptides and radionuclides.

HY-W717779

4-Aminobutyl-DOTA	Biochemical Assay Reagents
4-Aminobutyl-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. 4-Aminobutyl-DOTA can be used for conjugation of peptides and radionuclides.

HY-A0074

DTPA-tetra (t-Bu ester) tetra-tBu-DTPA	Biochemical Assay Reagents
DTPA-tetra (t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. DTPA-tetra (t-Bu ester) can be used for conjugation of peptides and radionuclides.

HY-W717800A

NO2A-Azide trihydrochloride	Biochemical Assay Reagents
NO2A-Azide (trihydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Azide (trihydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W1048555A

Mal-PEG2000-SCM

Biochemical Assay Reagents

Mal-PEG2000-SCM is a heterobifunctional PEG crosslinker bearing maleimide and succinimidyl carboxymethyl ester functional groups. MMal-PEG2000-SCM conjugates the F3 peptide to nanoparticles: the SCM group reacts with amino groups on the nanoparticle surface to form amide groups, while the MAL group reacts with thiol groups of the F3 peptide to form carbon-sulfur bonds. Mal-PEG-SCM enables unidirectional addition of linkers, ensuring that appropriate functional groups are available for RGD incorporation. Mal-PEG2000-SCM can be used in the development of nanoparticles targeting specific tumor cells .

HY-W451440

Butyne-DOTA-tris(t-butyl ester)	Biochemical Assay Reagents
Butyne-DOTA-tris(t-butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA-tris(t-butyl ester) can be used for conjugation of peptides and radionuclides.

HY-158066

p-NH2-Bn-NOTA hydrochloride hydrate	Biochemical Assay Reagents
p-NH2-Bn-NOTA (hydrochloride hydrate)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. p-NH2-Bn-NOTA (hydrochloride hydrate) can be used for conjugation of peptides and radionuclides.

HY-W053583R

Tetraxetan (Standard)

DOTA (Standard)

Biochemical Assay Reagents

Tetraxetan (Standard) is the analytical standard of Tetraxetan (HY-W053583). This product is intended for research and analytical applications. Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

HY-172473

DSPE-PEG2000-NGR	Biochemical Assay Reagents
DSPE-PEG2000-NGR is a PEG compound which composed of DSPE and an Asn-Gly-Arg (NGR) peptide. NGR peptide can target tumor vascular antigen CD13. DSPE-PEG2000-NGR can be used for drug delivery .

HY-131673A

(S)-p-SCN-Bn-TCMC hydrochloride	Biochemical Assay Reagents
(S)-p-SCN-Bn-TCMC (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (S)-p-SCN-Bn-TCMC (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-148646A

p-NH2-CHX-A"-DTPA hydrochloride hydrate	Biochemical Assay Reagents
p-NH2-CHX-A"-DTPA (hydrochloride hydrate)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-NH2-CHX-A"-DTPA (hydrochloride hydrate) can be used for conjugation of peptides and radionuclides.

HY-172497

DSPE-PEG2000-Mal-Cys-REKA	Biochemical Assay Reagents
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .

HY-172494A

DSPE-PEG3400-iRGD	Biochemical Assay Reagents
DSPE-PEG3400-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3400-iRGD can be used for drug delivery .

HY-138134

NOTP	Biochemical Assay Reagents
NOTPis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NOTP can be used for conjugation of peptides and radionuclides.

HY-W088413

DOTA-amide	Biochemical Assay Reagents
DOTA-amideis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-amide can be used for conjugation of peptides and radionuclides.

HY-W250844A

DO3A trisodium	Biochemical Assay Reagents
DO3A (trisodium)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DO3A (trisodium) can be used for conjugation of peptides and radionuclides.

HY-128890A

DOTA-NHS-ester hexafluorophosphate TFA	Biochemical Assay Reagents
DOTA-NHS-ester (hexafluorophosphate TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-NHS-ester (hexafluorophosphate TFA) can be used for conjugation of peptides and radionuclides.

HY-W782087A

p-SCN-Bn-PCTA hydrochloride	Biochemical Assay Reagents
p-SCN-Bn-PCTA (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-SCN-Bn-PCTA (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-172496

DSPE-PEG1000-Mal-Cys-REKA	Biochemical Assay Reagents
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .

HY-172498

DSPE-PEG5000-Mal-Cys-REKA	Biochemical Assay Reagents
DSPE-PEG5000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG5000-CREKA can be used for drug delivery .

HY-172497A

DSPE-PEG3400-Mal-Cys-REKA	Biochemical Assay Reagents
DSPE-PEG3400-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG3400-CREKA can be used for drug delivery .

HY-172492

DSPE-PEG5000-ESBP	Biochemical Assay Reagents
DSPE-PEG5000-ESBP is a PEG compound which composed of DSPE and a E-selectin-binding peptide (ESBP). As a tumor-targeting peptide, ESBP can specifically recognize and bind to receptors or markers on the surface of tumor cells .

HY-172495

DSPE-PEG3000-iRGD	Biochemical Assay Reagents
DSPE-PEG3000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3000-iRGD can be used for drug delivery .

HY-172493

DSPE-PEG1000-iRGD	Biochemical Assay Reagents
DSPE-PEG1000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG1000-iRGD can be used for drug delivery .

HY-138269A

Barzuxetan hydrochloride CHX-A''-DTPA-NCS hydrochloride	Biochemical Assay Reagents
Barzuxetan (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. Barzuxetan (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-134418A

NOTA trihydrochloride	Biochemical Assay Reagents
NOTA (trihydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NOTA (trihydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W717782

Bz-DTPA hydrochloride	Biochemical Assay Reagents
Bz-DTPA (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. Bz-DTPA (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W726767

DO2A	Biochemical Assay Reagents
DO2Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DO2A can be used for conjugation of peptides and radionuclides.

HY-W087027A

Maleimide-NOTA TFA	Biochemical Assay Reagents
Maleimide-NOTA (TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. Maleimide-NOTA (TFA) can be used for conjugation of peptides and radionuclides.

HY-158077

(R)-tetraMe-Tetraxetan (R)-tetraMe-DOTA	Biochemical Assay Reagents
(R)-tetraMe-Tetraxetanis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (R)-tetraMe-Tetraxetan can be used for conjugation of peptides and radionuclides.

HY-172473A

DSPE-PEG3400-NGR	Biochemical Assay Reagents
DSPE-PEG34000-NGR is a PEG compound which composed of DSPE and an Asn-Gly-Arg (NGR) peptide. NGR peptide can target tumor vascular antigen CD13. DSPE-PEG3400-NGR can be used for drug delivery .

HY-172272B

DSPE-PEG5000-A7R	Biochemical Assay Reagents
DSPE-PEG5000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .

HY-172272A

DSPE-PEG2000-Mal-Cys-ATWLPPR	Biochemical Assay Reagents
DSPE-PEG2000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .

HY-172272

DSPE-PEG1000-Mal-Cys-ATWLPPR	Biochemical Assay Reagents
DSPE-PEG1000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .

HY-172272C

DSPE-PEG3400-A7R	Biochemical Assay Reagents
DSPE-PEG3400-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .

HY-W717781A

p-NH₂-Bn-DTPA hydrochloride	Biochemical Assay Reagents
p-NH?-Bn-DTPA (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-NH?-Bn-DTPA (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W782088A

p-NH₂-Bn-PCTA hydrochloride	Biochemical Assay Reagents
p-NH?-Bn-PCTA (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-NH?-Bn-PCTA (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W749627

NO2A-Butyne	Biochemical Assay Reagents
NO2A-Butyneis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Butyne can be used for conjugation of peptides and radionuclides.

HY-W802013

DOTA-4AMP	Biochemical Assay Reagents
DOTA-4AMPis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-4AMP can be used for conjugation of peptides and radionuclides.

HY-158068

Maleimido-mono-amide-DTPA TFA	Biochemical Assay Reagents
Maleimido-mono-amide-DTPA (TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. Maleimido-mono-amide-DTPA (TFA) can be used for conjugation of peptides and radionuclides.

HY-W717833

NO2A-(t-Bu ester)	Biochemical Assay Reagents
NO2A-(t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-(t-Bu ester) can be used for conjugation of peptides and radionuclides.

HY-W782075

p-NO2-Bn-DOTA	Biochemical Assay Reagents
p-NO2-Bn-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NO2-Bn-DOTA can be used for conjugation of peptides and radionuclides.

HY-158069

p-NH₂-Bn-DTPA-penta (t-Bu ester)	Biochemical Assay Reagents
p-NH?-Bn-DTPA-penta (t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-NH?-Bn-DTPA-penta (t-Bu ester) can be used for conjugation of peptides and radionuclides.

HY-W460274

4-Aminobutyl-DOTA-tris(t-butyl ester)	Biochemical Assay Reagents
4-Aminobutyl-DOTA-tris(t-butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. 4-Aminobutyl-DOTA-tris(t-butyl ester) can be used for conjugation of peptides and radionuclides.

Cat. No.	Product Name	Target	Research Area

HY-P0122

iRGD peptide 5+ Cited Publications c(CRGDKGPDC)	Integrin	Cancer
iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.

HY-P10761

DPI-4452	Radionuclide-Drug Conjugates (RDCs) Carbonic Anhydrase	Cancer
DPI-4452 is a *CAIX*-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC₅₀ for recombinant hCAIX: 130 nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models . DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10709

CREKA peptide	Collagen	Cardiovascular Disease Cancer
CREKA peptide is a selective non-covalent binding agent targeting fibrin, type IV collagen, and fibronectin, often used as a targeting ligand to modify delivery carriers. CREKA peptide specifically recognizes fibrin, fibronectin, and type IV collagen that are excessively deposited in the tumor microenvironment or fibrotic tissue, mediating the targeted accumulation of the carrier at the lesion site and promoting drug internalization into target cells (such as cancer cells and activated hepatic stellate cells). CREKA peptide can enhance targeted delivery efficiency, increase drug concentration at the lesion site, and reduce systemic side effects .

HY-P4116

pH-Low Insertion Peptide pHLIP	Peptides	Metabolic Disease Cancer
pH-Low Insertion Peptide (pHLIP) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide successfully modify polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide-based targeting of cancer presents an opportunity to monitor metabolic changes, and to selectively deliver imaging and therapeutic agents to tumors .

HY-P11099

Cys-LT7	Transferrin Receptor	Neurological Disease Cancer
Cys-LT7 is a transferrin receptor (TfR)-targeting peptide ligand. Cys-LT7 binds to a TfR site distinct from endogenous transferrin, mediates conjugated Doxorubicin (HY-15142A) delivery to TfR-overexpressed tumor cells, and exhibits low toxicity to TfR-low-expressed normal cells. Cys-LT7 is an L-configuration peptide susceptible to proteolytic enzymes, leading to poor biostability in peptide-drug conjugates. Cys-LT7 can be used for the research of glioblastoma, hepatocellular carcinoma, lung carcinoma .

HY-P10762

Ricorfotide vedotin CBP-1008; LDC 10B	Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel	Cancer
Ricorfotide vedotin (CBP-1008) is a dual-ligand *peptide*-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .

HY-P10787

tLyP-1 peptide	Complement System	Cancer
tLyP-1 peptide is an NRP-1 targeting peptide with an IC₅₀ of 4 μM, and its amino acid sequence is CGNKRTR. tLyP-1 peptide specifically binds to NRP-1 to target tumor cells .

HY-P10449

M2 Peptide	Peptides	Inflammation/Immunology Cancer
M2 Peptide is a peptide targeting M2-like tumor-associated macrophages (TAMs). M2 Peptide is used to carry drugs or small interfering RNA (siRNA) to promote the repolarization of M2-like macrophages to M1-like macrophages, thereby altering the immunosuppressive state in the tumor microenvironment and enhancing the anti-tumor immune response. M2 Peptide can be used to study the effect of macrophage polarization and how this polarization change affects tumor growth and metastasis .

HY-P10131

3BP-3940	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases .

HY-P3440

WL12	Radionuclide-Drug Conjugates (RDCs) PD-1/PD-L1	Cancer
WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression .

HY-P11108

RP-182	NF-κB Apoptosis TNF Receptor Caspase	Inflammation/Immunology Cancer
RP-182 is a synthetic immunomodulatory peptide that exerts anti-tumor effects by targeting the mannose receptor CD206 (K_d = 8 μM) on the surface of tumor-associated macrophages (TAMs). RP-182 induces a conformational switch of the CD206 receptor, which activates NF-κB signaling and phagocytosis in CD206 ^high TAMs. RP-182 has dual function: activation of canonical NF-κB signaling, triggering TNFα secretion and autocrine activation of the TNF receptor 1 (TNFR1), leading to activation of caspase 8, apoptosis, and cell death. RP-182 is used in pancreatic cancer and melanoma research .

HY-P3441A

3BP-4089 TFA	FAP	Cancer
3BP-4089 TFA is a highly efficient fibroblast activation protein (FAP) targeting peptide. 3BP-4089 TFA is often conjugated with radionuclides for tumor diagnosis and research .

HY-P11294

KLVVVGADGVGKSALTI	Ras	Cancer
KLVVVGADGVGKSALTI is a KRAS G12D targeting peptide that can be used in tumor research .

HY-P10493

NY-ESO-1 (157-165) peptide	Amino Acid Derivatives	Cancer
NY-ESO-1 (157-165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .

HY-113003

H-γ-Glu-Gln-OH γ-Glutamylglutamine; γ-Glu-Gln	Peptides	Others Cancer
H-γ-Glu-Gln-OH is a hydrophilic peptide and can be conjugated to drugs. The carrier composed of H-γ-Glu-Gln-OH has the characteristics of high water solubility and drug-loading capacity, good biocompatibility, low toxicity, improved tumor targeting ability, and anti-tumor efficacy .

HY-P10501A

FRα-targeting peptide C7 TFA	Antifolate	Cancer
FRα-targeting peptide C7 TFA is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 TFA can be used in the research of tumor diagnosis and treatment .

HY-P10709A

CREKA peptide acetate	Biochemical Assay Reagents	Cardiovascular Disease Cancer
CREKA peptide acetate is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. CREKA peptide acetate can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .

HY-P10792

HER2-targeted peptide H6F	EGFR	Cancer
HER2-targeted peptide H6F is a HER2 targeting peptide that binds to HER2 to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .

HY-P4091

LSD	Biochemical Assay Reagents	Cancer
LSD is a peptide. LSD can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD can reduce the number of tumor lymphatics. LSD can be used in the research of targeted therapy and diagnosis of tumor lymphatics .

HY-P10934

LXY3 LXY2	Integrin	Cancer
LXY3 (LXY2) is a VLA-3-blocking peptide that inhibits the interaction between integrin α3β1 (VLA-3) on neutrophil surfaces and laminin in the basement membrane, thereby preventing neutrophil migration across the tumor vascular basement membrane barrier. LXY3 is used to block neutrophil-mediated nanoparticle release from perivascular pools into the tumor interstitium. LXY3 is commonly employed for targeted imaging of breast cancer .

HY-P10740

CBP-1018	Peptide-Drug Conjugates (PDCs) PSMA Folate Receptor (FR)	Cancer
CBP-1018 is a PDC (peptide-drug conjugate) formed by conjugating Monomethyl auristatin E (HY-15162) to a dual-targeting ligand of FLOR1/PSMA (prostate-specific membrane antigen) via a linker (HY-78738). CBP-1018 binds to FLOR1 and prostate-specific membrane antigen (PSMA). CBP-1018 is applicable to the research of solid tumors and metastatic castration-resistant prostate cancer .

HY-P3441

3BP-4089	FAP	Cancer
3BP-4089 is a highly efficient fibroblast activation protein (FAP) targeting peptide. 3BP-4089 is often conjugated with radionuclides for tumor diagnosis and research .

HY-P10679

GPLGLAGGWGERDGS	MMP	Cancer
GPLGLAGGWGERDGS is a peptide with MMP enzyme responsiveness and tumor targeting function, which can be used to monitor enzyme-guided nanoparticle assembly in tumors .

HY-P1828A

EGFRvIII peptide (PEPvIII) TFA	EGFR	Cancer
EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide TFA represents a truly tumor-specific target for antitumor immunotherapy .

HY-P4116A

pH-Low Insertion Peptide TFA pHLIP TFA	Peptides	Metabolic Disease Cancer
pH-Low Insertion Peptide TFA (pHLIP TFA) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide TFA targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide TFA successfully modifys polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide TFA -based targeting of cancer presents an opportunity to monitor metabolic changes and to selectively deliver imaging and therapeutic agents to tumors .

HY-P4089

REA	Peptides	Cancer
REA is a homing peptide that targets pre-cancerous tumor lymphatic vessels. REA homes to lymphatic vessels at the pre-cancerous tumor stage, but does not recognize tumor lymphatic vessels. REA can be used in pre-cancerous tumor research .

HY-P10894

mUNO	Epigenetic Reader Domain	Cancer
mUNO is a tumor-homing peptide (mUNO, sequence: "CSPGAK") that specifically binds to mouse CD206, targeting tumor-associated macrophages that express CD206/MRC1. mUNO can interact with human recombinant CD206 .

HY-P11084

WT1 126-134 peptide	MHC	Inflammation/Immunology Cancer
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (K_d = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies .

HY-P10772

L2P4	Peptide-Drug Conjugates (PDCs) EBV	Cancer
L2P4 is a peptide-based and EBNA1 targeting fluorescent probe, which inhibits the EBNA1 homodimer formation and selectively inhibits EBV+ tumor growth. L2P4 exhibits cytotoxicity in EBV-positive C666-1 cell with LC₅₀ of 46.4 μM .

HY-P10772A

L2P4 TFA	Peptide-Drug Conjugates (PDCs) EBV	Cancer
L2P4 TFA is a peptide-based and EBNA1 targeting fluorescent probe, which inhibits the EBNA1 homodimer formation and selectively inhibits EBV+ tumor growth. L2P4 TFA exhibits cytotoxicity in EBV-positive C666-1 cell with LC₅₀ of 46.4 μM .

HY-P11026

DOTA-TMVP1446 DOTA-PEG4-TMVP1446	VEGFR	Cancer
DOTA-TMVP1446 is a VEGFR-3 targeting peptide. DOTA-TMVP1446 labeled with ⁶⁸Ga accurately detectes the status of lymph node metastasis, even in micrometastatic tumors, in the B16-F10 tumor mice model. DOTA-TMVP1446 can be used as a radiotracer for cancer-metastatic sentinel lymph nodes (m-SLN) imaging .

HY-P4903

RGD-targeted Proapoptotic Peptide	Peptides	Cancer
RGD-targeted Proapoptotic Peptide is a peptide. The C-terminal RGD-4C peptide (ACDCRGDCFC) binds preferentially to integrins at sites of tumor angiogenesis.

HY-P1828

EGFRvIII peptide (PEPvIII)	EGFR	Cancer
EGFRvIII peptide (PEPvIII) is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide represents a truly tumor-specific target for antitumor immunotherapy .

HY-P11286

A7RC	Complement System	Cancer
A7RC is a multifunctional peptide used in tumor-targeted therapy, with Cysteine added to the C-terminal of the A7R peptide (sequence: ATWLPPR). A7R (HY-P1663) is a ligand of the NRP-1 receptor, regulating intracellular signal transduction related to tumor vascularization and tumor growth .

HY-P10493A

NY-ESO-1 (157-165) peptide TFA	Amino Acid Derivatives	Cancer
NY-ESO-1 (157-165) peptide (TFA) is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide (TFA) can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide (TFA) is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .

HY-178489

BGC1614	Nectin-4	Cancer
BGC1614 is a *Nectin-4*-targeting bicyclic toxin conjugate (BTC) belonging to the category of peptide-drug conjugates (PDCs). BGC1614 exhibits strong targeted binding ability to Nectin-4, with an K_D of 3.859 × 10 ^-7 M. BGC1614 exhibits superior antitumor efficacy in nude mice bearing PC-3 and N87 tumor xenografts. BGC1614 can be used for research related to Nectin-4-overexpressing tumors (such as prostate cancer, gastric cancer) .

HY-P10087

Mouse TREM-1 SCHOOL peptide Mouse TREM-1(213–221), GF9	Peptides	Inflammation/Immunology Cancer
Mouse TREM-1 SCHOOL peptide (Mouse TREM-1(213-221), GF9) targets the interaction between TREM-1 and its signaling partner DAP-12, specifically silencing the TREM-1 signaling pathway, regulate the production of TREM-1-mediated pro-inflammatory cytokines in vivo and in vitro. Mouse TREM-1 SCHOOL peptide has anti-tumor effects. Mouse TREM-1 SCHOOL peptide can reduce the formation of vitreoretinal neovascularization .

HY-P10444

DOTA Conjugated JM#21 derivative 7	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10978

NK224	PD-1/PD-L1	Cancer
NK224 is a peptide-based radiotracer targeting human PD-L1, with dual-radionuclide ( ⁶⁸Ga and ¹⁸F) labeling compatibility enabled by the NOTA chelator. NK224 exhibits high binding affinity to PD-L1, with an IC₅₀ value of 2.45 nM. NK224 visualizes intrapatient tumor heterogeneity and dynamically monitors PD-L1 target occupancy during immunotherapy. NK224 can be used for the study of non-small cell lung cancer (NSCLC) .

HY-P10501

FRα-targeting peptide C7	Antifolate	Cancer
FRα-targeting peptide C7 is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 can be used in the research of tumor diagnosis and treatment .

HY-P10786

LinTT1 peptide	Transmembrane Glycoprotein	Cancer
LinTT1 peptide is a tumor-penetrating peptide with the amino acid sequence AKRGARST. LinTT1 peptide targets peritoneal carcinoma (PC) by binding to the p32 (gC1qR) receptor. It can conjugate with iron oxide nanoworms (NWs) to form a nanocarrier. This nanocarrier is taken up by peritoneal carcinoma cells in vitro and enters the mitochondria; it also exhibits significant tumor targeting and penetration effects in mice. Moreover, LinTT1-functionalized nanocarriers, combined with the pro-apoptotic peptide [D(KLAKLAK)2], show significant tumor suppression in a mouse peritoneal tumor model. LinTT1 peptide holds promise as a delivery carrier for peritoneal cancer research .

HY-P5520

GB-6	Bombesin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
GB-6 is a short linear peptide that targets the gastrin releasing peptide receptor (GRPR). GRPR is overexpressed in pancreatic cancer. Based on the tumor selectivity and tumor-specific accumulation properties of GB-6, GB-6 labeled with near infrared (NIR) fluorescent dyes or radionuclide netium-99m (99mTc) can be used as a high-contrast imaging probe. GB-6 has excellent in vivo stability, with tumor to pancreatic and intestinal fluorescence signal ratios of 5.2 and 6.3, respectively, in SW199 0 subcutaneous xenograft models. GB-6 can rapidly target tumors and accurately delineate tumor boundaries, which has broad application prospects .

HY-P11089

TP53 neoepitope	MHC	Cancer
TP53 neoepitope is a high-affinity antigenic peptide targeting HLA-A. TP53 neoepitope can triggers CD8 ⁺ T cell-mediated killing of TP53-mutant tumor cells. TP53 neoepitope is promising for research of solid tumors harboring TP53 hotspot mutations (e.g., R175H, R273H) .

HY-P11011

Peptide R54 Pep R54; CXCR4 antagonist peptide 19	CXCR	Cancer
Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic peptide targeting CXCR4 with significant anticancer activity. Peptide R54 inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and lung metastasis development, with better serum stability and higher CXCR4 affinity than the lead compound (IC₅₀=20 nM). Peptide R54 synergizes with anti-PD-1 therapy to exert anti-tumor activity in vivo, enhances granzyme activity, and reduces infiltration of Foxp3 cells. Peptide R54 can be used in the study of colon cancer, ovarian cancer, and melanoma .

HY-P10947

MACTIDE-V	Epigenetic Reader Domain YAP	Cancer
MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206 ⁺ tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models .

HY-P10417

RTDLDSLRTYTL	Integrin IFNAR	Cancer
RTDLDSLRTYTL is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL can be used in the research of cancer immunotherapy and targeted drug development .

HY-P11108A

RP-182 acetate	NF-κB Apoptosis TNF Receptor Caspase	Inflammation/Immunology Cancer
RP-182 acetate is a synthetic immunomodulatory peptide that exerts anti-tumor effects by targeting the mannose receptor CD206 (K_d = 8 μM) on the surface of tumor-associated macrophages (TAMs). RP-182 acetate induces a conformational switch of the CD206 receptor, which activates NF-κB signaling and phagocytosis in CD206 ^high TAMs. RP-182 acetate has dual function: activation of canonical NF-κB signaling, triggering TNFα secretion and autocrine activation of the TNF receptor 1 (TNFR1), leading to activation of caspase 8, apoptosis, and cell death. RP-182 acetate is used in pancreatic cancer and melanoma research .

HY-P10775A

BT1769 acetate	MMP	Cancer
BT1769 acetate is a conjugate and antitumor agent targeting MT1-MMP, with a K_d value of 3.35 nM against human targets. BT1769 acetate exhibits favorable pharmacokinetic properties. BT1769 acetate specifically binds to MT1-MMP via its bicyclic peptide component, delivering the cytotoxic agent MMAE (HY-15162) to antigen-expressing cells. It effectively inhibits tumor growth, induces complete responses, and significantly prolongs event-free survival in osteosarcoma patient-derived xenograft models. BT1769 acetate shows extremely low activity in Ewing sarcoma models and can be used in osteosarcoma-related research .

HY-P10971

Nef-M1	CXCR Apoptosis VEGFR GSK-3 Cadherin Caspase	Cancer
Nef-M1 (Nef-Motif-1) is an antagonist peptide targeting CXCR4 and an apoptosis inducer derived from a myristoylated protein encoded by the nef gene in HIV. Nef-M1 inhibits tumor angiogenesis and epithelial-mesenchymal transition (EMT). Nef-M1 activates the apoptosis pathway by increasing the level of caspase-3 in cancer cells. Nef-M1 simultaneously inhibits VEGF-A, p-GSK-3β and vimentin, and enhances E-cadherin, thereby inhibiting angiogenesis and EMT processes. Nef-M1 can be used in the study of colorectal cancer and breast cancer .

HY-P3707

Tumor targeted pro-apoptotic peptide	Apoptosis	Cancer
Tumor targeted pro-apoptotic peptide (CNGRC-GG-D(KLAKLAK)2) is an anti-tumor peptide. Tumor targeted pro-apoptotic peptide disrupts mitochondrial membranes and promotes apoptosis, showing anticancer activity in mice .

Cat. No.	Product Name	Target	Research Area	Image

HY-P3371

Ifinatamab deruxtecan DS-7300a; MABX-9001a; I-DXd	Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis	Cancer
Ifinatamab deruxtecan (DS-7300a) is a *B7-H3*-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects

HY-P99339

Tebentafusp IMCgp100	Interleukin Related TNF Receptor	Cancer
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor* cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .

HY-P990717

Brenetafusp IMC-F106C	CD3	Cancer
Brenetafusp is a TCR/anti-CD3 bispecific fusion protein, consisting of a TCR targeting the PRAME peptide and an anti-CD3 scFv effector domain. Brenetafusp redirects CD3 ⁺ T cells to kill PRAME ⁺ tumor cells. Brenetafusp can be used in research related to cutaneous melanoma, non-small cell lung cancer, ovarian cancer, endometrial cancer, triple-negative breast cancer, and small cell lung cancer .

Cat. No.	Product Name		Classification

HY-W539916

Azido-mono-amide-DOTA		Azide
Azido-mono-amide-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Azido-mono-amide-DOTA can be used for conjugation of peptides and radionuclides.

HY-W782078

Butyne-DOTA		Alkynes
Butyne-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA can be used for conjugation of peptides and radionuclides.

HY-W717800A

NO2A-Azide trihydrochloride		Azide
NO2A-Azide (trihydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Azide (trihydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W451440

Butyne-DOTA-tris(t-butyl ester)		Alkynes
Butyne-DOTA-tris(t-butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA-tris(t-butyl ester) can be used for conjugation of peptides and radionuclides.

HY-W749627

NO2A-Butyne		Alkynes
NO2A-Butyneis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Butyne can be used for conjugation of peptides and radionuclides.

HY-W749614

NO2A-Butyne-bis(t-Butyl ester)		Alkynes
NO2A-Butyne-bis(t-Butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Butyne-bis(t-Butyl ester) can be used for conjugation of peptides and radionuclides.

Cat. No.	Product Name		Classification

HY-172494

DSPE-PEG2000-iRGD		Pegylated Lipids
DSPE-PEG2000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG2000-iRGD can be used for agent delivery .

HY-172473

DSPE-PEG2000-NGR		Pegylated Lipids
DSPE-PEG2000-NGR is a PEG compound which composed of DSPE and an Asn-Gly-Arg (NGR) peptide. NGR peptide can target tumor vascular antigen CD13. DSPE-PEG2000-NGR can be used for drug delivery .

HY-172497

DSPE-PEG2000-Mal-Cys-REKA		Pegylated Lipids
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .

HY-172494A

DSPE-PEG3400-iRGD		Pegylated Lipids
DSPE-PEG3400-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3400-iRGD can be used for drug delivery .

HY-172496

DSPE-PEG1000-Mal-Cys-REKA		Pegylated Lipids
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .

HY-172498

DSPE-PEG5000-Mal-Cys-REKA		Pegylated Lipids
DSPE-PEG5000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG5000-CREKA can be used for drug delivery .

HY-172497A

DSPE-PEG3400-Mal-Cys-REKA		Pegylated Lipids
DSPE-PEG3400-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG3400-CREKA can be used for drug delivery .

HY-172492

DSPE-PEG5000-ESBP		Pegylated Lipids
DSPE-PEG5000-ESBP is a PEG compound which composed of DSPE and a E-selectin-binding peptide (ESBP). As a tumor-targeting peptide, ESBP can specifically recognize and bind to receptors or markers on the surface of tumor cells .

HY-172495

DSPE-PEG3000-iRGD		Pegylated Lipids
DSPE-PEG3000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3000-iRGD can be used for drug delivery .

HY-172493

DSPE-PEG1000-iRGD		Pegylated Lipids
DSPE-PEG1000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG1000-iRGD can be used for drug delivery .

HY-172473A

DSPE-PEG3400-NGR		Pegylated Lipids
DSPE-PEG34000-NGR is a PEG compound which composed of DSPE and an Asn-Gly-Arg (NGR) peptide. NGR peptide can target tumor vascular antigen CD13. DSPE-PEG3400-NGR can be used for drug delivery .

HY-172272B

DSPE-PEG5000-A7R		Pegylated Lipids
DSPE-PEG5000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .

HY-172272A

DSPE-PEG2000-Mal-Cys-ATWLPPR		Pegylated Lipids
DSPE-PEG2000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .

HY-172272

DSPE-PEG1000-Mal-Cys-ATWLPPR		Pegylated Lipids
DSPE-PEG1000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .

HY-172489

DSPE-PEG5000-K237		Pegylated Lipids
DSPE-PEG5000-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG5000-K237 can be used for drug delivery .

HY-172488

DSPE-PEG2000-K237		Pegylated Lipids
DSPE-PEG2000-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG2000-K237 can be used for drug delivery .

HY-172487

DSPE-PEG1000-K237		Pegylated Lipids
DSPE-PEG1000-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG1000-K237 can be used for drug delivery .

HY-172491

DSPE-PEG2000-ESBP		Pegylated Lipids
DSPE-PEG2000-ESBP is a PEG compound which composed of DSPE and a E-selectin-binding peptide (ESBP). As a tumor-targeting peptide, ESBP can specifically recognize and bind to receptors or markers on the surface of tumor cells .

HY-172490

DSPE-PEG1000-ESBP		Pegylated Lipids
DSPE-PEG1000-ESBP is a PEG compound which composed of DSPE and a E-selectin-binding peptide (ESBP). As a tumor-targeting peptide, ESBP can specifically recognize and bind to receptors or markers on the surface of tumor cells .

HY-172474

DSPE-PEG5000-NGR		Pegylated Lipids
DSPE-PEG5000-NGR is a PEG compound which composed of DSPE and an Asn-Gly-Arg (NGR) peptide. NGR peptide can target tumor vascular antigen CD13. DSPE-PEG5000-NGR can be used for drug delivery .

HY-172472

DSPE-PEG1000-NGR		Pegylated Lipids
DSPE-PEG1000-NGR is a PEG compound which composed of DSPE and an Asn-Gly-Arg (NGR) peptide. NGR peptide can target tumor vascular antigen CD13. DSPE-PEG1000-NGR can be used for drug delivery .

HY-172488A

DSPE-PEG3400-K237		Pegylated Lipids
DSPE-PEG3400-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG3400-K237 can be used for drug delivery .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Tumor targeting peptide

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Click Chemistry

Oligonucleotides

Natural
Products